focus -WSS

focus

author：Wikipedia 2025-10-01 01:50:27 - browse：818

Blood corpuscles in clot — Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success. David Gregory & Debbie Marshall/Wellcome Images

Vascular device maker Inari Medical announced plans to buy LimFlow, a company selling a last-line therapy to save legs with blocked blood flow, on Wednesday. Inari will pay $250 million upfront and $165 more depending on LimFlow’s commercial success.

LimFlow recently snagged Food and Drug Administration approval for its surgical system that uses a stent to connect a blocked artery to an open vein, thus allowing blood to flow through and heal injuries. The tool is meant only for patients with a severe form of peripheral artery disease, and who have already tried more conservative options.

Dan Rose, CEO of LimFlow, previously told STAT that his mission is to fight the amputation epidemic in the United States, which disproportionately impacts Black patients. Experts cautioned to STAT that expanding screenings to catch the disease early is still the most important measure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Food makers tried to stack nutrition panel with preferred experts

focus

WSS

Patient advocates sound warning on FDA proposal on salt intake

Liz Cheney makes 1st public comment since Trump's election interference indictments

Private equity could exacerbate cardiology's overuse problem, experts fear

Pig kidney works a record two months in donated body

Baltimore teen accused of firing into crowd during block party mass shooting

Telehealth for opioid use disorder is lifesaving

leisure time

focus

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Trump cancels press conference intended to dispute Georgia election interference charges

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Liz Cheney makes 1st public comment since Trump's election interference indictments

Psychedelics group wrestles with new pharma identity

The pain doctors face in trying to build their families

Novavax promises a turnaround & Lilly roils the obesity market

New details revealed about Purdue's marketing of OxyContin

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Ukraine taking heavy casualties 10 weeks into its counteroffensive

knowledge

Evacuations in place as 3 wildfires burn in eastern Washington state

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Will the IRA bring competition to the biologics market?

Listen: Racing for gene therapy & a pioneering approval

Eye stem cell transplant could help restore vision in injured people

How to make the FDA’s new prescription one

leisure time

leisure time

focus

hotspot